



Patent
Attorney's Docket No. 032396-011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)

WRIGHT et al.)

Application No.: 08/886,313)

Filed: June 30, 1997)

For: INHIBITING NEOPLASTIC CELLS)
UTILIZING THE RIBONUCLEOTIDE)
REDUCTASE UTR)

Group Art Unit: 1635

Examiner: M. Shibuya

REPLY TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JUL 03 2000

Sir:

TECH CENTER 1600/2900

Enclosed is a reply for the above-identified patent application.

☒ A Reply to the Restriction Requirement mailed on June 5, 2000.


☒ No fee is required.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,


BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:



Leslie J. Boley
Registration No. 41,490

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300
Date: June 28, 2000



Patent
Attorney's Docket No. 032396-011

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
WRIGHT et al.) Group Art Unit: 1635
)
Application No.: 08/886,313) Examiner: M. Shibuya
)
Filed: June 30, 1997)
)
For: INHIBITING NEOPLASTIC CELLS)
UTILIZING THE)
RIBONUCLEOTIDE REDUCTASE)
UTR)

10/a
501
7/8/00

REPLY TO REQUIREMENT FOR RESTRICTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

JUL 03 2000

This Reply is submitted in response to the requirement for restriction which was mailed on June 5, 2000. It is submitted before its due date of July 5, 2000. Entry of the following amendments and consideration of the following remarks is respectfully requested.

AMENDMENTS

In the Claims:

✓ Please cancel claims 18-29 and 32-34 without prejudice or disclaimer.

REMARKS

Claims 1-34 are currently pending in this application and stand restricted under 35 U.S.C. §121 into the following five groups defined in the Office Action:

Group I: Claims 1-17 and 30, drawn to an oligonucleotide corresponding to the entire untranslated 3' region of a housekeeping gene, and pharmaceutical compositions comprising said oligonucleotides, or antisense thereof, or ribozymes complementary to at least a portion of said UTR, classifiable in class 536, subclass 24.5;